EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling

Jin Dong iD, Luna Prieto Garcia iD, Yingbo Huang iD, Weifeng Tang iD, Anna Lundahl, Marie Elebring, Christine Ahlström, Anna Vildhede, Erik Sjögren iD, Mats Någård iD

Clinical Pharmacology & Therapeutics · 2023

DOI: 10.1002/cpt.2980 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2023. Verfasst von Jin Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A different drug–drug interaction (DDI) scenario may exist in patients with chronic kidney disease (CKD) compared with healthy volunteers (HVs), depending on the interplay between drug–drug and disease (drug‐drug‐disease interaction (DDDI)). Physiologically‐based pharmacokinetic (PBPK) modeling, in lieu of a clinical trial, is a promising tool for evaluating these complex DDDIs in patients. However, the prediction confidence of PBPK modeling in the severe CKD population is still low when nonrenal pathways are involved. More mechanistic virtual disease population and robust validation cases are needed. To this end, we aimed to: (i) understand the implications of severe CKD on statins (atorvastatin, simvastatin, and rosuvastatin) pharmacokinetics (PK) and DDI; and (ii) predict untested clinical scenarios of statin‐roxadustat DDI risks in patients to guide suitable dose regimens. A novel virtual severe CKD population was developed incorporating the disease effect on both renal and nonrenal pathways. Drug and disease PBPK models underwent a four‐way validation. The verified PBPK models successfully predicted the altered PKs in patients for substrates and inhibitors and recovered the observed statin‐rifampicin DDIs in patients and the statin‐roxadustat DDIs in HVs within 1.25‐ and 2‐fold error. Further sensitivity analysis revealed that the severe CKD effect on statins PK is mainly mediated by hepatic BCRP for rosuvastatin and OATP1B1/3 for atorvastatin. The magnitude of statin‐roxadustat DDI in patients with severe CKD was predicted to be similar to that in HVs. PBPK‐guided suitable dose regimens were identified to minimize the risk of side effects or therapeutic failure of statins when co‐administered with roxadustat.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsRenal Insufficiency, ChronicHumansAtorvastatinRosuvastatin CalciumATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsDrug InteractionsModels, BiologicalComputer Simulation

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsAtorvastatinRosuvastatin CalciumATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm Proteins

Autor:innen und Institutionen

  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Drug Metabolism and Pharmacokinetics, Research and Early Development Cardiovascular, Renal and Metabolism, BioPharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden.
  • Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
  • Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Jin Dong, Luna Prieto Garcia, Yingbo Huang, Weifeng Tang, Erik Sjögren, Mats Någård

Förderung

  • AstraZeneca

Zitieren

APA

Dong, J., Prieto Garcia, L., Huang, Y., Tang, W., Lundahl, A., Elebring, M., Ahlström, C., Vildhede, A., Sjögren, E., & Någård, M. (2023). Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.2980

Vancouver

Dong J, Prieto Garcia L, Huang Y, Tang W, Lundahl A, Elebring M, et al. Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2980

BibTeX
@article{Dong2023,
  author = {Dong, Jin and Prieto Garcia, Luna and Huang, Yingbo and Tang, Weifeng and Lundahl, Anna and Elebring, Marie and Ahlström, Christine and Vildhede, Anna and Sjögren, Erik and Någård, Mats},
  title = {Understanding Statin‐Roxadustat Drug–Drug‐Disease Interaction Using Physiologically‐Based Pharmacokinetic Modeling},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1002/cpt.2980}
}
Kostenlos starten →